ANTX — AN2 Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Anterix, Fidus Investment, Nextpower
Brief: AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement Of Oral An2-502998 To Phase 2 Study For Chronic Chagas Disease
AN2 Therapeutics' Q1 net loss narrows as R&D costs fall
Brief: AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies
Brief: An2 Therapeutics Inc - Enters Open Market Sale Agreement With Jefferies For Up To $80 Million Common Stock - SEC Filing
Brief: An2 Therapeutics Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing
AN2 Therapeutics' Q4 net loss widens on higher R&D expenses
Brief: AN2 Therapeutics Announces Plans To Advance Oral Epetraborole Into Phase 2 Study For Polycythemia Vera (PV)
AN2 Therapeutics Q3 net loss narrows to $9.4 mln
U.S. STOCKS ON THE MOVE-Eli Lilly, Fossil, Papa John's
U.S. STOCKS ON THE MOV-Guardant Health, Tower Semiconductor, GlobalFoundries
U.S. STOCKS ON THE MOVE-Instacart, Plug Power, Crypto stocks
AN2 Therapeutics jumps after GSK collaboration to develop tuberculosis treatment
Brief: AN2 Therapeutics Announces Research Collaboration With GSK
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary